Kite Pharma (KITE) Being Defended At Cowen & Co.
Tweet
Share
E-mail
Get Alerts KITE Hot Sheet
Price: $179.79 --0%
Rating Summary:
10 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
10 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Kite Pharma (NASDAQ: KITE) shares are being defended at Cowen & Co. by analyst Eric Schmidt the firm has confirmed to Street Insider. Schmidt and his team believe the patient death is a "non-event" and does not expect any impact to the opportunity available for the CAR-T drug.
The company confirms to clients that they are buyers of the stock, specifically "aggressive" buyers with stock trading down over 10 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- TD Cowen Reiterates Buy Rating on Broadcom Limited (AVGO), neutral into the print
- Snowflake Inc. (SNOW) PT Raised to $370 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
